Leica Biosystems, Indica Labs, and Lunit are collaborating to enhance AI-driven digital pathology, specifically for PD-L1 biomarker analysis, aiming to streamline and standardize pathology workflows in precision oncology research.
The partnership builds on an existing collaboration between Leica Biosystems and Indica Labs, now incorporating Lunit's advanced AI capabilities. This integration is set to enhance the quantification of PD-L1 and other immunohistochemistry biomarkers, providing a more consistent and scalable approach to biomarker scoring through computational pathology tools. The initial product from this collaboration is the Lunit SCOPE algorithm, which is designed for use with Leica's PD-L1 primary antibody.
Leica Biosystems will leverage this partnership to assist pharmaceutical companies in embedding AI-driven digital pathology into their clinical research processes. Traditional biomarker scoring methods are often inconsistent and labor-intensive, relying heavily on manual evaluations. By merging the strengths of Leica’s IHC staining technology, Indica Labs’ image management systems, and Lunit’s AI analysis, the collaboration aims to enhance the reliability of biomarker assessments and expedite research workflows.
This integration signifies a commitment to advancing open pathology and interoperability within the field. As noted by Karan Arora from Leica Biosystems, the goal is to create a seamless workflow for users, reflecting a broader vision of integrating scalable research capabilities into clinical practice. This initiative marks a significant step toward harnessing AI’s potential in digital pathology.